← All trials
NCT00028990
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2001
- Primary completion
- Nov 1, 2006
- Completion date
- May 1, 2009
- First posted
- —
- Last posted
- —
- Enrollment
- 722
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Eastern Cooperative Oncology GroupLead sponsor
- Elkhart General HospitalOfficial
- Mayo ClinicStudy chair
- British Columbia Cancer AgencyStudy chair
- Rush UniversityStudy chair
- Indiana UniversityStudy chair
- National Cancer Institute (NCI)Collaborator
- North Central Cancer Treatment GroupCollaborator
- NSABP FoundationCollaborator
- Canadian Cancer Trials GroupCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.